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Objectives. We sought to determine the cost advantage of a
strategy of same-sitting diagnostic catheterization and percutane-
ous transluminal coronary angioplasty (PTCA) (ad hoc) in com-
parison with staged PTCA.
Background. It is widely assumed that an ad hoc strategy lowers
costs by reducing the length of hospital stay (LOS). However, this
assumption has not been examined in a contemporary data set.
Methods. We studied 395 patients undergoing PTCA during 6
consecutive months. Cost analysis was performed using standard
cost-accounting methods and a mature cost-accounting system.
Costs were examined within three clinical strata based on the
indication for PTCA (stable angina, unstable angina and after
myocardial infarction [MI]).
Results. For the entire patient cohort, there was no significant
cost advantage of an ad hoc approach within any of the strata,
although there was a nonsignificant trend toward an ad hoc
approach in patients with stable angina. For patients treated with
conventional balloon PTCA alone, the lack of a significant differ-
ence between ad hoc and staged strategies persisted. For patients
who received stents, there was a significant cost advantage of an
ad hoc approach in all three clinical strata. An important cost
driver was the occurrence of complications. Differences in the
rates of complications did not reach statistical significance be-
tween ad hoc and staged strategies, but even a small trend toward
greater complications in patients who had the ad hoc strategy
negated cost and LOS advantages. Our study had the power to
detect significant cost differences of $1,300 for patients with stable
angina, $2,100 for patients with unstable angina and $2,500 for
post-MI patients. It is possible that we failed to detect smaller cost
advantages as significant.
Conclusions. A cost savings with an ad hoc strategy of PTCA
could not be consistently demonstrated. The cost advantage of an
ad hoc approach may be most readily realized in clinical settings
where the intrinsic risks are low (e.g., stable angina) or in which
the device used carries a reduced risk of complications (e.g.,
stenting), because even a small increase in the complication rate
will negate any financial advantage of an ad hoc approach.
(J Am Coll Cardiol 1998;31:321–5)
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Percutaneous transluminal coronary angioplasty (PTCA) per-
formed during the same sitting as diagnostic coronary angiog-
raphy, so-called “ad hoc” PTCA, continues to generate con-
troversy (1–4). The focus of the debate has been the safety of
an ad hoc approach. The underlying assumption of pursuing an
ad hoc strategy is that a more rapid and definitive resolution of
the ischemic coronary problem will yield significant cost sav-
ings through shortened length of hospital stay (LOS) and
improved patient convenience (5,6). The cost advantage of an
ad hoc strategy has been evaluated only once previously, in a
data set from a decade ago (4). Our aim was to examine the
economics of ad hoc versus staged PTCA strategies in a
contemporary data set.
Methods
Four hundred eighty-one patients underwent PTCA during
6 consecutive months (November 1995 through April 1996).
For all PTCAs, clinical data gathered included an indication
for the procedure (stable angina, unstable angina, after myo-
cardial infarction [MI], acute MI, cardiogenic shock and
“other”), age, gender, urgency of intervention (emergent,
urgent, nonurgent), number of diseased vessels, number of
lesions dilated, American College of Cardiology/American
Heart Association lesion class (A, B1, B2 or C), ejection
fraction and use of preprocedural intravenous heparin and
nitroglycerin.
Our cost-accounting system is a mature one that systemat-
ically and comprehensively captures fixed and variable costs
using accepted accounting methods. Each patient care activity
has assigned to it a cost that has been derived by summing all
identified variable costs as well as an allocated component of
fixed costs. The allocation of institutional overhead to cost
centers (such as the catheterization laboratory) is based on
activity-based costing (i.e., costs of support services are allo-
cated in proportion to the degree to which the clinical center
uses the support service). Subsequent cost-center overhead
and fixed costs are assigned to specific patient care activities by
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a collaborative process involving the cost center manager and
the cost-accounting staff. The cost accountants ensure that all
costs are allocated comprehensively and in accordance with
standard cost-accounting methods, whereas the managers as-
sess that costs assigned to specific patient care activities
represent a fair and equitable allocation. Cost information is
linked to each patient charge code. An individual patient’s cost
summary is thus derived from his or her itemized hospital bill.
For staged elective procedures, the costs of the preceding
diagnostic catheterization and its associated hospital stay were
added to the costs of the PTCA admission. We excluded staged
procedures in which the diagnostic catheterization had been
performed at another institution (n 5 48), as we had no
reliable means of accounting for costs incurred before admis-
sion to our hospital.
To have a meaningful comparison between staged and ad
hoc procedures, we stratified patients according to the indica-
tion for PTCA. We have previously demonstrated that the
clinical context within which PTCA is undertaken is an impor-
tant determinant of overall costs (7). Failure to account for
differences in case mix would bias the results. We therefore
excluded patients who had primary PTCA for acute MI (n 5
34) and cardiogenic shock (n 5 3), as these procedures were,
by definition, uniformly ad hoc. No comparable staged proce-
dures exist. These two groups have considerably higher costs
than other patient groups, and their inclusion would unfairly
bias the results against the ad hoc group. Similarly, one patient
in the ad hoc group was classified as having an “other”
indication and was excluded from analysis. Thus we had three
groups of patients: stable angina (n 5 111), unstable angina
(n 5 179) and post-MI (n 5 105).
We compared total costs of ad hoc versus staged PTCAs
within each of the three clinical strata. To compare dichoto-
mized variables we used chi-square analysis, and to compare
continuous variables we used analysis of variance. Data are
presented as the mean value 6 SD.
Finally, to search for confounding variables, we performed
several analyses. We examined if there were different rates of
ad hoc procedures among the eight interventionalists; appar-
ent economic differences in ad hoc versus staged strategies
could have reflected the idiosyncratic practice characteristics
of a given operator if that operator disproportionately per-
formed his or her procedures either ad hoc or staged. Further-
more, we performed a multiple stepwise regression analysis to
identify the baseline characteristics that were significant cost
drivers. We then used the significant factors to adjust the case
mix and repeated our analysis of ad hoc versus staged approaches.
Results
Patient characteristics are shown in Table 1. In general, the
patients treated with ad hoc angioplasty and staged angioplasty
were comparable with a few notable differences. Some patients
in the ad hoc group, in both the unstable angina and post-MI
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
LOS 5 length of stay
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
Table 1. Patient Characteristics
Stable Angina Unstable Angina Post-MI
Ad Hoc
(n 5 42)
Staged
(n 5 69)
p
Value
Ad Hoc
(n 5 95)
Staged
(n 5 84)
p
Value
Ad Hoc
(n 5 67)
Staged
(n 5 38)
p
Value
Age (yr) 61.4 6 11.6 63.1 6 11.0 NS 60.7 6 12.6 61.1 6 12.5 NS 57.9 6 12.3 57.8 6 10.5 NS
% male 76% 65% NS 57% 69% 0.09 64% 79% NS
Emergent procedure 0% 0% NS 8 (8%) 0 (0%) 0.007 10 (15%) 0 (0%) 0.01
Urgent procedure 1 (2%) 2 (3%) NS 55 (58%) 37 (44%) 0.09 36 (54%) 13 (34%) 0.05
Heparin before PTCA 3 (7%) 6 (9%) NS 79 (83%) 62 (74%) NS 57 (85%) 28 (74%) NS
IV NTG before PTCA 0% 0% NS 32 (34%) 19 (23%) NS 29 (43%) 8 (21%) 0.02
No. of diseased coronary
arteries
1.45 6 0.63 1.70 6 0.81 NS 1.73 6 1.32 1.77 6 1.79 NS 1.31 6 0.56 1.65 6 0.82 0.01
No. of lesions dilated 1.43 6 0.59 1.49 6 0.63 NS 1.17 6 0.50 1.32 6 0.59 0.07 1.19 6 0.53 1.35 6 0.63 NS
Lesion class (AHA/ACC)
A 11 (26%) 23 (33%) NS 22 (23%) 10 (12%) NS 11 (16%) 5 (13%) NS
B 29 (69%) 45 (65%) 68 (72%) 67 (80%) 54 (81%) 31 (82%)
C 2 (5%) 1 (1%) 5 (5%) 7 (8%) 2 (3%) 2 (5%)
Technologies used
Conventional PTCA 15 (36%) 29 (42%) NS 51 (54%) 37 (44%) NS 41 (61%) 25 (66%) NS
Intracoronary stent 26 (62%) 39 (57%) NS 43 (45%) 44 (52%) NS 26 (39%) 13 (34%) NS
DCA 0 0 NS 0 2 (2%) NS 0 0 NS
Rotational ablation 1 (2%) 1 (1%) NS 1 (1%) 2 (2%) NS 0 0 NS
Data are presented as mean value 6 SD or number (%) of patients. AHA/ACC 5 American Heart Association/American College of Cardiology; DCA 5
directional coronary atherectomy; IV 5 intravenous; MI 5 myocardial infarction; NTG 5 nitroglycerin; PTCA 5 percutaneous transluminal coronary angioplasty.
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categories, underwent PTCA in an emergency setting,
whereas, by definition, none of the staged procedures were
done on an emergency basis. Furthermore, for post-MI pa-
tients, more of the patients in the ad hoc group were receiving
antecedent nitroglycerin. In contrast, post-MI patients who
had a staged procedure tended to have more extensive coro-
nary disease. The trend toward treating more lesions per
patient in patients with unstable angina who had a staged
procedure was of borderline significance. The use of various
interventional technologies is detailed in Table 1 and did not
differ between the ad hoc and staged PTCA groups.
The overall outcomes are shown in Table 2. The LOS did
not differ between the ad hoc and staged groups in any of the
clinical strata. There was a cost savings of borderline signifi-
cance with an ad hoc strategy in patients with stable angina.
Patients with unstable angina or post-MI patients who were
treated in an ad hoc fashion tended to incur a greater
frequency of complications, although this trend was not statis-
tically significant. The power of our study to detect a significant
increase in complications was limited, however. The chance of
a beta error was .0.5 to fail to detect as significant (at p ,
0.05) a difference in complications between ad hoc and staged
strategies of 7.4% and 4.2%, respectively (the actual rates in
the current study). Complications were an important driver of
costs. Patients with complications had significantly higher costs
than patients without complications. For patients with stable
angina, the occurrence of a complication added, on average,
$2,853 to the cost of care (p 5 0.03). For unstable angina and
post-MI, the excess marginal costs for complications were
$10,810 (p , 0.0001) and $1,993 (p 5 NS), respectively. We
also performed power calculations to determine the amount of
cost savings that would have been necessary to achieve a beta
error of ,0.2 and to detect as significant (p , 0.05) a cost
difference between the two strategies, given the sample size in
the present study. For patients with stable angina, the savings
would have to have been .$1,300, for unstable angina .$2,100
and for post-MI .$2,500. Our study, therefore, lacked power
to detect smaller cost advantages as significant.
The analyses based on whether patients underwent conven-
tional PTCA alone or received stents are summarized in Table
2. For conventional PTCA, there were no significant differ-
ences between staged or ad hoc strategies for any of the
comparisons. There were trends, however, toward lower costs
with an ad hoc strategy in patients with stable angina and
toward lower costs with a staged strategy for patients with
unstable angina or for post-MI patients. For patients who
received stents, in all cases an ad hoc strategy had significantly
lower overall costs as compared with the staged strategy.
The rates of ad hoc procedures were not significantly
different among our eight operators and ranged from 43% to
67% of cases. Multivariate analysis identified one variable
significantly negatively correlated with costs (stable angina as
indication for PTCA) and five variables significantly correlated
with increasing costs (MI and shock as indications, number of
lesions dilated, age and diabetes mellitus). Whether PTCA was
performed staged or ad hoc was not a significant independent
variable. When using these variables to adjust the case mix,
there was no overall difference between the two strategies (ad
hoc $4,736 6 7,580 vs. staged $4,692 6 3,734, p 5 NS). The
differences between ad hoc and staged strategies for the three
clinical strata were also not significantly different. For stable
angina, the difference was $764 in favor of an ad hoc approach
(p 5 0.14); for unstable angina the difference was $83 in favor
of an ad hoc approach (p 5 NS); and for post-MI the
difference was $162 in favor of a staged approach (p 5 NS).
Discussion
Our study demonstrated that an ad hoc strategy of PTCA
does not consistently lead to an economic advantage over a
Table 2. Costs, Length of Stay and Complications
Stable Angina Unstable Angina Post-MI
Ad Hoc Staged
p
Value Ad Hoc Staged
p
Value Ad Hoc Staged
p
Value
All Cases
Costs $6,295 6 2,414 $7,199 6 2,679 0.08 $9,218 6 7,557 $ 9,599 6 4,170 NS $ 9,470 6 5,536 $ 9,712 6 4,599 NS
Range $ 3,224–13,167 $ 2,254–13,212 $ 2,347–66,955 $ 1,494–23,254 $ 4,220–33,224 $ 2,893–18,448
LOS (days) 2.7 6 1.6 2.8 6 2.0 NS 5.7 6 4.5 7.0 6 5.8 NS 6.2 6 5.3 5.9 6 3.2 NS
Range 1–6 1–10 1–26 2–44 2–36 1–13
Complications 1 (2.4%) 3 (4.3%) NS 8 (8.4%) 4 (4.8%) NS 6 (9.0%) 1 (2.6%) NS
Conventional PTCA Cases
Costs $4,890 6 2,805 $5,623 6 1,709 NS $9,065 6 9,612 $ 8,312 6 4,296 NS $ 9,074 6 6,490 $ 8,067 6 3,752 NS
LOS 1.8 6 1.3 2.2 6 1.5 NS 6.6 6 5.5 6.5 6 3.4 NS 6.3 6 6.2 5.2 6 3.0 NS
Stent Cases
Costs $7,124 6 1,801 $8,462 6 2,613 0.03 $9,206 6 4,120 $10,875 6 3,796 , 0.05 $10,094 6 3,586 $12,876 6 4,535 , 0.05
LOS 3.3 6 1.5 3.3 6 2.2 NS 4.2 6 1.7 7.6 6 7.3 0.04 6.1 6 3.1 7.2 6 3.3 NS
Data presented are mean value 6 SD, range or number (%) of patients. LOS 5 length of hospital stay; other abbreviations as in Table 1.
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staged strategy. In some clinical settings, ad hoc PTCA was
associated with lower costs, whereas in others it was not.
Furthermore, the cost advantage, when it occurred, was mod-
est.
In recent years, ad hoc PTCA has become increasingly
common, as operators have overcome concerns regarding
patient safety and preparedness, surgical backup and potential
errors from interventions, based on digital images in the
catheterization laboratory (8). In the present study, the trend
toward greater complications with ad hoc PTCA strategies in
patients with unstable angina, post-MI patients or in the entire
cohort did not reach statistical significance, although our study
was underpowered to detect this difference. Two similar-sized
studies also identified nonsignificant trends toward increased
rates of MI or coronary artery bypass graft surgery (CABG)
complicating ad hoc PTCA, and the investigators concluded
that an ad hoc strategy did not pose any increased risk (1,2).
Kimmel et al. (5), however, examined a much larger number of
patients and reported significantly greater rates of MI, CABG
or death with an ad hoc approach. The economic importance
of even a modest trend toward increased complications is
greatly magnified by excessive costs. The high costs of even a
few complications can quickly negate the cost advantage of
shortening the LOS with an ad hoc strategy.
In contrast to our study, O’Keefe et al. (4) reported a
significant cost savings with ad hoc PTCA. Their estimate of
cost, however, was derived from hospital charges, not direct
cost accounting. This methodology has substantial shortcom-
ings (9,10). Furthermore, their study was undertaken before
the availability of intracoronary stents and other second-
generation interventional devices, which are major contribu-
tors to the cost of interventional procedures (11–13).
One variable that may contribute to the lack of consistent
clinical and economic advantage of ad hoc PTCA is that of
operator selection. Low volume operators with reduced access
to catheterization laboratory time may feel the greatest com-
punction to perform ad hoc PTCA, lest they lose the oppor-
tunity to perform the procedure. Furthermore, these same
operators may be selecting the most marginal cases if they feel
pressured to maintain their volume. It is not likely that such a
selection bias played a major role in our study. Although the
eight operators in our center varied in the number of years’
experience in performing PTCA, they were a very homoge-
neous group in terms of overall annual volume and complica-
tion rates. Furthermore, there were no significant differences
in the rates of ad hoc PTCA among our operators, thus making
it unlikely that the idiosyncratic practice patterns of any one
individual impacted substantially on the overall result.
The cost advantage of an ad hoc strategy was realized in
settings where safety appears to be enhanced. Thus, our
patients with stable angina, an intrinsically low risk group, had
a trend toward lower complications and lower costs with an ad
hoc strategy. Furthermore, in all of our clinical strata, patients
with stents had lower costs with an ad hoc strategy. Because
stenting is effective in addressing dissections and has been
associated with falling complication rates (14), it may be safe
and cost-saving to perform ad hoc PTCA in patients with
coronary lesions of a morphology and caliber suitable for
stenting. It would be of interest to examine whether the size of
the coronary arteries differed among our ad hoc and staged
PTCA and stent groups, but we did not collect this data
prospectively. Similarly, the use of glycoprotein IIb-IIIa block-
ers has been shown to reduce the risks of PTCA-related
complications in an economically viable manner (15). Abcix-
imab was available during the course of this study and was used
at the discretion of the individual operator. We did not
systematically track pharmacologic agents used in the cathe-
terization laboratory and cannot conclude whether abciximab
can contribute to a safe or cost-effective ad hoc strategy.
Our study also suggests that the LOS advantages of an ad
hoc strategy may not be realized in some clinical settings. Our
post-MI patients, for example, did not have lower costs or a
shortened LOS. If the overall LOS is being driven by the fact
that the patient sustained an MI, then completing the PTCA a
day earlier in the hospital period may not translate into any
savings. Although it was proposed nearly 10 years ago that
early PTCA may promote early discharge of patients with MI
(16), a recent large registry report failed to document any
shortened LOS with PTCA (17).
Conclusions. An ad hoc strategy of PTCA does not achieve
cost savings uniformly in all clinical settings. Even a small
increment in complications will negate the cost savings of a
shortened LOS. Furthermore, the cost advantages, when real-
ized, were rather modest. The cost advantage of an ad hoc
strategy was most likely to be realized in settings associated
with enhanced safety.
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